5-(3-(5-aminopyrazin-2-yl)-4-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one | 1373940-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-(3-(5-aminopyrazin-2-yl)-4-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one
• 英文别名: 5-[3-(5-Aminopyrazin-2-yl)-4-chlorophenyl]-3-methyl-1,3,4-oxadiazol-2-one
• CAS: 1373940-19-2
• 化学式: C₁₃H₁₀ClN₅O₂
• 分子量: 303.708
• InChiKey: OAHRWKODEAYPAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  申请人：Irlapati Nageswara Rao

  公开号：US20130225600A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式（I）的化合物及其制备方法，这些化合物对于治疗、预防和/或管理与CRAC调节相关的疾病、紊乱、综合症或状况是有用的。本发明还涉及使用式（I）的化合物治疗、预防、管理和/或减轻与CRAC调节相关的疾病、紊乱、综合症或状况的方法。
• OXAZOLE AND ISOXAZOLE CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160022673A1

  公开（公告）日：2016-01-28

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及公式（I）的化合物及其制备方法，用于治疗、预防和/或管理与CRAC调节相关的疾病、疾病、综合征或病况。本发明还涉及使用公式（I）的方法来治疗、预防、管理和/或减轻与CRAC调节相关的疾病、疾病、综合征或病况。
• Oxazoline and isoxazoline derivatives as CRAC modulators
  申请人：LUPIN LIMITED

  公开号：US10292981B2

  公开（公告）日：2019-05-21

  The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式（I）化合物、 及其制备工艺，可用于治疗、预防和/或控制与调节 CRAC 有关的疾病、失调、综合征或病症。本发明进一步涉及治疗、预防、控制和/或减轻与式（I）的 CRAC 调节相关的疾病、失调、综合症或病症的方法。
• US9169242B2
  申请人：——

  公开号：US9169242B2

  公开（公告）日：2015-10-27
• US9737534B2
  申请人：——

  公开号：US9737534B2

  公开（公告）日：2017-08-22